Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial.

Pomerantz LLP is investigating claims of securities fraud against Altimmune, Inc. (NASDAQ: ALT) and its officers and directors. The investigation concerns the company's announcement of positive topline results from its IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). Investors who have held Altimmune shares are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Investors in Altimmune, Inc. (NASDAQ: ALT) are advised to be cautious following an investigation by Pomerantz LLP into potential securities fraud. The probe focuses on Altimmune's announcement of positive topline results from its IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). Investors who held Altimmune shares are urged to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Goldman Sachs recently downgraded Altimmune to a 'Sell' rating, citing concerns over pemvidutide's clinical profile and the crowded market landscape [1]. The investment bank noted that while Altimmune maintains a strong liquidity position, the company faces significant challenges in completing clinical development without a partnership or additional funding. Other analysts, however, maintain more optimistic views, with price targets ranging from $6 to $28.

Altimmune has enrolled the first patient in its RESTORE Phase 2 trial evaluating pemvidutide for Alcohol-Associated Liver Disease (ALD). The trial aims to enroll around 100 patients to assess the drug's effectiveness over a 48-week period [2]. The company's lead asset, pemvidutide, is a dual GLP-1/GCGR agonist being developed for obesity and related conditions, with a focus on liver-specific diseases including MASH. The drug has shown promising results in previous trials, with statistically significant reductions in liver fat and markers of fibrosis, as well as improvements in blood pressure and weight loss [2].

Despite the positive results from the IMPACT trial, Altimmune faces regulatory and market challenges. The company's Phase 2b trial for MASH demonstrated significant weight loss and favorable tolerability but did not achieve statistically significant improvements in fibrosis. This mixed response from the investment community has led to varying analyst ratings, with some maintaining a 'Buy' rating and others downgrading the stock [1].

Investors should closely monitor the ongoing investigation by Pomerantz LLP and Altimmune's clinical trial results. The company's ability to navigate regulatory hurdles and secure partnerships or additional funding will be crucial in determining its future success.

References:
[1] https://za.investing.com/news/analyst-ratings/goldman-sachs-downgrades-altimmune-stock-to-sell-on-pemvidutide-concerns-93CH-3784116
[2] https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-initiation-restore-phase-2-trial-evaluating